Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers
European Thyroid Journal · 01.06.2026 · 15 (3)
DOI: 10.1530/etj-25-0301 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Thyroid Journal, online erschienen am 13.04.2026. Verfasst von Edoardo Talpacci und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Anaplastic thyroid carcinoma (ATC) is an extremely aggressive cancer, traditionally refractory to conventional treatments. The combined therapy with lenvatinib and pembrolizumab (L + P) is supported by a preclinical rationale based on the distinctive immunological profile of ATC. We propose a real-life study to evaluate relevant clinical outcomes and identify survival predictors in a cohort of ATC patients treated with the combined therapy in two Italian referral centers.
Methods
Sixteen ATC patients treated with the combination of L + P were retrospectively included. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were assessed according to RECIST 1.1 criteria. Baseline patient characteristics, including immuno-nutritional status (calculated using the CONUT score), were analyzed to identify potential predictors of response.
Results
A median OS of 10 months (95% CI: 4.2–15.9 months) and a median PFS of 6.0 months (95% CI: 0–12.7 months) were observed after L + P therapy. Complete response was observed in 6.2% and partial response in 31.3% of patients, resulting in an ORR of 37.5%; the DCR was 68.8%. Progressive disease occurred in 25% of patients. Furthermore, a baseline CONUT score ≤ 2 resulted in a significantly longer OS (log-rank, P = 0.001) and PFS (P = 0.05) compared to CONUT score ≥ 3, while a non-significantly longer OS was observed between patients with a baseline ECOG PS of 0–2 and those with a baseline ECOG PS ≥ 3.
Conclusion
Our study confirms the efficacy and safety of L + P therapy, identifying the CONUT score as a prognostic factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
- Department of Biomedical Sciences, Humanitas University, Milano, Italy.
ORCID-Profile: Cosimo Durante, Giorgio Grani, Efisio Puxeddu
Zitieren
APA
Talpacci, E., Macera, M., Maida, G., Morelli, S., Leone, V., Ingriccini, C., Ferrieri, A., Tortoriello, R., Paci, M., Baldoni, M., Morelli, O., Barp, S., Sponziello, M., Maranghi, M., Durante, C., Grani, G., & Puxeddu, E. (2026). Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers. European Thyroid Journal, 15(3). https://doi.org/10.1530/etj-25-0301
Vancouver
Talpacci E, Macera M, Maida G, Morelli S, Leone V, Ingriccini C, et al. Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers. European Thyroid Journal. 2026;15(3). doi:10.1530/etj-25-0301
BibTeX
@article{Talpacci2026,
author = {Talpacci, Edoardo and Macera, Manuela and Maida, Giulia and Morelli, Silvia and Leone, Vincenzo and Ingriccini, Chiara and Ferrieri, Antonella and Tortoriello, Rachele and Paci, Miriam and Baldoni, Monia and Morelli, Olivia and Barp, Samuele and Sponziello, Marialuisa and Maranghi, Marianna and Durante, Cosimo and Grani, Giorgio and Puxeddu, Efisio},
title = {Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers},
journal = {European Thyroid Journal},
year = {2026},
volume = {15},
number = {3},
doi = {10.1530/etj-25-0301}
}
EUVIMED